Molecular Partners AG (MOLN) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates...

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG...

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as...

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T...

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile...

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of...

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement...

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have...

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced...

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]